MANE
Veradermics, Incorporated
NYSE · Healthcare · Biotechnology · US
$98.51
+0.78%Income statement
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Expenses | ||||
| R&D Expense | 62.7M | 62.1M | 23.3M | 15.0M |
| SG&A Expense | 25.7M | 10.3M | 3.5M | 2.4M |
| General & Admin Expense | 25.7M | 10.3M | 3.5M | 2.4M |
| Selling & Marketing Expense | — | — | — | — |
| Other Expenses | — | — | — | — |
| Total Operating Expenses | 88.4M | 72.3M | 26.8M | 17.3M |
| Cost and Expenses | 88.4M | 72.3M | 26.8M | 17.3M |
| Operating Income (EBIT) | (88.4M) | (72.3M) | (26.8M) | (17.3M) |
| Non-Operating | ||||
| Interest Income | 8.4M | 1.6M | 481.0K | 870.0K |
| Interest Expense | 824.0K | — | 585.0K | 36.0K |
| Net Interest Income | 7.6M | 1.6M | (104.0K) | 834.0K |
| Other Non-Op Income/Expense | 10.2M | 2.4M | 290.0K | 834.0K |
| Non-Operating Income (excl Interest) | (4.9M) | (2.4M) | (875.0K) | (870.0K) |
| EBT (Pre-Tax Income) | (78.2M) | (70.0M) | (26.5M) | (16.5M) |
| Income Tax Expense | — | — | — | — |
| Bottom Line | ||||
| Net Income | (78.2M) | (70.0M) | (26.5M) | (16.5M) |
| Earnings from Cont. Ops | (78.2M) | (70.0M) | (26.5M) | (16.5M) |
| Earnings from Discont. Ops | — | — | — | — |
| Bottom Line Net Income | (88.2M) | (83.4M) | (27.3M) | (16.5M) |
| Per Share | ||||
| Basic EPS | ($2.17) | ($2.38) | ($0.14) | ($0.08) |
| Diluted EPS | ($2.17) | ($2.38) | ($0.14) | ($0.08) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | ||||
| Basic Shares Outstanding | 40.4M | 35.1M | 201.3M | 201.3M |
| Diluted Shares Outstanding | 40.4M | 35.1M | 201.3M | 201.3M |
| Profitability Metrics | ||||
| EBITDA | (83.5M) | (70.0M) | (25.9M) | (16.5M) |
| D&A | — | — | — | — |
| EBIT | (83.5M) | (70.0M) | (25.9M) | (16.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026